CRDF

insider transactions

Cardiff Oncology, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 11, 26

Lale White

Director

$0

40.6K sh

Own +26%
Grant·A
Jun 11, 26

Renee P Tannenbaum

Director

$0

40.6K sh

Own +24%
Grant·A
Jun 11, 26

Rodney S Markin

Director

$0

40.6K sh

Own +18%
Grant·A
Jun 11, 26

Gary W Pace

Director

$0

40.6K sh

Own +22%
Grant·A
Jun 11, 26

James O Armitage

Director

$0

40.6K sh

Own +22%
Grant·A
Apr 27, 26

Ajay Aggarwal

Chief Operating Officer

$0

400.0K sh

Own New
Grant·A
Apr 14, 26

Tod Smeal

Chief Scientific Officer

$0

300.0K sh

Own +31%
Grant·A
Apr 6, 26

Joshua B Muntner KEY

Chief Financial Officer

$0

486.6K sh

Own +97330%
Grant·A
Apr 6, 26

Joshua B Muntner KEY

Chief Financial Officer

$0

486.6K sh

Own +97330%
Grant·A
Mar 31, 26

Mani Mohindru KEY

Chief Executive Officer

$0

600.0K sh

Own +163%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 11, 2026	Lale White	Director	Grant A	40.6K	+26%	—	$0
Jun 11, 2026	Renee P Tannenbaum	Director	Grant A	40.6K	+24%	—	$0
Jun 11, 2026	Rodney S Markin	Director	Grant A	40.6K	+18%	—	$0
Jun 11, 2026	Gary W Pace	Director	Grant A	40.6K	+22%	—	$0
Jun 11, 2026	James O Armitage	Director	Grant A	40.6K	+22%	—	$0
Apr 27, 2026	Ajay Aggarwal	Chief Operating Officer	Grant A	400.0K	New	—	$0
Apr 14, 2026	Tod Smeal	Chief Scientific Officer	Grant A	300.0K	+31%	—	$0
Apr 6, 2026	Joshua B Muntner KEY	Chief Financial Officer	Grant A	486.6K	+97330%	—	$0
Apr 6, 2026	Joshua B Muntner KEY	Chief Financial Officer	Grant A	486.6K	+97330%	—	$0
Mar 31, 2026	Mani Mohindru KEY	Chief Executive Officer	Grant A	600.0K	+163%	—	$0

About CRDF insider trading

This page tracks insider transactions for Cardiff Oncology, Inc. (CRDF) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.